Quite a week for this company, all of it presumably in anticipation of the pancreatic cancer results in late July at AACR.
If this is effective in pancreatic without even being optimized for the best antigens, it has the potential to be effective across tumor types, at least those that are immunologically accessible. Could this be the first true pan-tumor treatment?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.